John Gordon: The immune landscape of more than 1,000 tumors across ten different cancers using CPTAC pan-cancer proteogenomic data
John Gordon, VP Scientific Affairs, Co-Founder, Director at Celentyx Ltd shared the following on LinkedIn:
“Characterisation of Tumor Immunity | Tour-de-Force Study Reveals Seven Immune Subtypes Spanning Ten Cancer Types | OPEN ACCESS at Cell Press|
Despite the successes of immunotherapy in cancer treatment over recent decades, less than <10%–20% cancer cases have demonstrated durable responses from immune checkpoint blockade. To enhance the efficacy of immunotherapies, combination therapies suppressing multiple immune evasion mechanisms are increasingly contemplated.
Here*, to better understand immune cell surveillance and diverse immune evasion responses in tumor tissues, Francesca Petralia, Weiping Ma, Tomer M. Yaron-Barir et al. comprehensively characterized the immune landscape of more than 1,000 tumors across ten different cancers using CPTAC pan-cancer proteogenomic data.
They identified seven distinct immune subtypes based on integrative learning of cell type compositions and pathway activities. They then thoroughly categorized unique genomic, epigenetic, transcriptomic, and proteomic changes associated with each subtype. Further leveraging the deep phosphoproteomic data, they studied kinase activities in different immune subtypes, which revealed potential subtype-specific therapeutic targets.
Insights from this work will facilitate the development of future immunotherapy strategies and enhance precision targeting with existing agents.”
Read further.
Source: John Gordon/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023